News

In an interview with Targeted Oncology, Courtney DiNardo, MD, MSCE, discussed what oncologists should know about ivosidenib and the drug’s potential in treating hematologic malignancies.

After issuing a complete response letter in May 2023, the FDA has now accepted the resubmission of the biologics license application of a drug regimen for the treatment of non-muscle-invasive bladder cancer.

In an interview with Targeted Oncology, Francis P. Worden, MD, discussed data from the COSMIC-311 study which support treatment with cabozantinib for patients with radioiodine-refractory differentiated thyroid cancer.

October is Liver Cancer Awareness Month, and strides continue to be made in the realm of liver cancer diagnosis and treatment. Two experts, Joan Culpepper-Morgan, MD, and Susanne G. Warner, MD, shed light on some of the treatment options available in the space.

A phase 2 study of neoadjuvant gemcitabine, cisplatin, plus nivolumab met its co-primary end point with a positive predictive value of clinical complete response of 0.97 among patients with muscle-invasive bladder cancer.

Preclinical data of MB-109 from the American Association for Cancer Research Annual Meeting in 2022 support MB-109 as a potential treatment for patients with recurrent glioblastoma.

TTX101 will be studied in a phase 1/2a clinical trial for patients with recurrent glioblastoma.

In an interview with Peers and Perspectives in Oncology, Tim Showalter, MD, MPH, discussed increasing patient quality of life by using artificial intelligence and precision medicine to inform cancer treatment decisions.

ARX517 showed early efficacy in patients with metastatic castration-resistant prostate cancer in the phase 1/2 APEX-01 study.

Adam Brufsky, MD, PhD, FACP, discusses background and next steps of the phase 3 PALOMA-2 study which evaluated palbociclib plus letrozole in patients that identified as Black or Hispanic with advanced breast cancer.

A study published in the Journal of the American College of Cardiology found that chimeric antigen receptor T-cell therapy was associated with fewer major cardiac events than previously thought. 

In an interview with Targeted Oncology, Federico Albrecht, MD, discussed advances to treatments for patients with small cell lung cancer and considerations when treating difficult cases.

The primary end point of progression-free survival was met in TROPION-Breast01, a phase 3 study of datopotamab deruxtecan for patients with hormone receptor-positive/HER2-negative breast cancer.

Ivosidenib tablets have received FDA approval for the treatment of adult patients with relapsed/refractory myelodysplastic syndromes with a susceptible IDH1 mutation.

Lisa B. Ercolano, MD, discusses some of the advances that have been seen in the treatment of sarcomas.

In an interview with Targeted Oncology, Yi Lin, MD, PhD, discussed the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.

Over three-fourths of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer treated with TAR-200 achieved complete responses in the phase 2b SUNRISE-1 trial.

In an interview with Targeted Oncology during the International Liver Cancer Association Annual Conference 2023, Tim F. Greten, MD, discussed the key highlights from his presentation on tissue biopsy, and his thoughts on the opposing argument in favor of liquid biopsy.

Treatment with datopotamab deruxtecan improved progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer.

In a phase 2 study, frontline bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride was well tolerated in patients with B-cell non-Hodgkin marginal zone lymphoma.

Amivantamab-vmjw with lazertinib showed positive survival results vs osimertinib as frontline therapy for patients with advanced non–small cell lung cancer harboring classical EGFR sensitizing mutations.

Lindsey S. Treviño, PhD, discusses some of the disparities that currently exist among patients with cancer.

Pembrolizumab and mRNA-4157 demonstrated improvements in subgroups of resected melanoma, including those with BRAF-mutated tumors, in the phase 2 KEYNOTE-942 trial.

The safety run-in of the LEAP-014 trial showed acceptable toxicity and antitumor responses in patients with metastatic esophageal cancer receiving pembrolizumab, lenvatinib, and chemotherapy consisting of cisplatin plus either paclitaxel or 5-fluororacil.

An exploratory analysis of Study 309/KEYNOTE-775 showed further benefit for patients and consistent safety in patients who received pembrolizumab plus lenvatinib for advanced endometrial cancer who continued lenvatinib treatment.

A novel CD20xCD3 bispecific antibody showed promising safety and preliminary antitumor activity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.